[在不同风险人群中使用注射性黄胺的新结果研究]
André Scheen1, Pierre Delanaye2, Patrizio Lancellotti3
1Service de Diabétologie, Nutrition et Maladies métaboliques et Unité de Pharmacologie clinique, CHU Liège, ULiège, Belgique.
Revue medicale de Liege
|October 14, 2024
概括
注射性塞马格卢提德有效地控制了2型糖尿病,改善了血糖和减轻体重. 最近的试验证实了它在高风险患者中的心血管和脏益处.
科学领域:
- 药理学 药理学是指药理学的学科.
- 内分泌学 在内分泌学.
- 心脏病学 心脏病学
背景情况:
- 塞马格卢提德 (每周1毫克) 是一种高效的GLP-1受体激动剂,用于2型糖尿病 (T2D).
- 在SUSTAIN-6试验中,在心血管风险高的T2D患者中确定了其安全性和心血管 (CV) 疗效.
- 随后的试验已经在各种高风险人群中探索了它的好处.
研究的目的:
- 在各种患者群体中审查塞马格卢提德的疗效和安全性.
- 突出其在T2D管理和扩大治疗应用中的既定作用.
- 强调其在预防心血管和脏疾病方面的好处.
主要方法:
- 对包括SUSTAIN-6,FLOW,STEP-HFpEF和SELECT在内的关键安慰剂对照随机试验的审查.
- 分析与血糖控制,减肥,心血管事件和功能相关的结果.
- 包括使用1毫克和2.4毫克每周剂量塞马格卢提德的研究.
主要成果:
- 塞马格卢提德 (1毫克) 在T2D的血糖控制和体重减轻方面表现出卓越的疗效.
- 试验证实了显著的心血管益处,并改善了高风险人群的预后.
- 在T2D和CKD患者,HFpEF肥胖患者和确定的动脉样硬化心血管疾病患者中观察到积极的结局.
结论:
- 塞马格卢提德是T2D的高效治疗方法,除了血糖控制之外,它还提供了显著的好处.
- 在主要心血管和脏结局试验中,其已被证明的疗效扩大了其治疗效用.
- 对于患有心血管和脏疾病高风险的患者来说,塞马格卢提德是一种有价值的选择.
相关概念视频
01:24Glucagon-like Receptor Agonists
301
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
301
01:16Insulin: Dosing Regimen and Adverse Effects
152
Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
152
01:06Oral Hypoglycemic Agents: Glinides
142
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
142
01:23Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
123
Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
123
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
178
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
178
01:23Dipeptidyl Peptidase 4 Inhibitors
173
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
173